Premium
NS 5A inhibitors for the treatment of hepatitis C infection
Author(s) -
Gitto Stefano,
Gamal Nesrine,
Andreone Pietro
Publication year - 2017
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12657
Subject(s) - potency , hepatitis c , clinical trial , clinical efficacy , medicine , viral replication , protease , in vitro , virology , protease inhibitor (pharmacology) , hepatitis c virus , pharmacology , human immunodeficiency virus (hiv) , biology , viral load , antiretroviral therapy , virus , enzyme , biochemistry
Today, we are witnessing a new era for the treatment of hepatitis C with excellent rates of virologic response and very good safety profiles. Among the many classes of direct‐acting antivirals, the inhibitors of nonstructural protein 5A are particularly interesting. NS 5A is a phosphorylated protein with a relevant role in viral replication. HCV ‐ NS 5A inhibitors show high potency, very good safety profile and high barrier to resistance. The amazing in vitro effectiveness of this class is associated with great efficacy in clinical trials in combination protocols with antivirals of other classes, with sustained virological response ( SVR ) obtained in more than 90% of patients. Herein, we sought to review the current knowledge regarding the NS 5A protease complex inhibitors with special emphasis on clinical efficacy and development of viral resistance.